The global onco-hematology molecular testing market is projected to reach US$ 1.5 Billion by 2031, driven by the increasing prevalence of hematological cancers and advancements in molecular diagnostic technologies. These tests are crucial for accurate diagnoses, personalized treatment plans, and monitoring disease progression, making them essential for effective cancer care.